Vor Biopharma (VOR) Competitors

$15.52 +0.81 (+5.51%)

Closing price 04:00 PM Eastern

Extended Trading

$15.38 -0.14 (-0.87%)

As of 05:29 PM Eastern

VOR vs. GPCR, ARQT, DNLI, GMTX, and DYN

Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Denali Therapeutics (DNLI), Gemini Therapeutics (GMTX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does Vor Biopharma compare to Structure Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Structure Therapeutics (NASDAQ:GPCR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

: Structure Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vor Biopharma N/A N/A N/A -$386.83 N/A
Structure Therapeutics N/A N/A -$141.20M -$0.79 N/A
: In the previous week, Structure Therapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Structure Therapeutics and 6 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.92 beat Structure Therapeutics' score of 0.75 indicating that Vor Biopharma is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vor Biopharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Structure Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its share price is 231% less volatile than the S&P 500.
: Vor Biopharma's return on equity of 0.00% beat Structure Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Vor Biopharma N/A N/A N/A
Structure Therapeutics N/A -25.90% -24.54%
: Vor Biopharma presently has a consensus target price of $50.56, suggesting a potential upside of 225.74%. Structure Therapeutics has a consensus target price of $109.25, suggesting a potential upside of 165.82%. Given Vor Biopharma's higher probable upside, equities analysts clearly believe Vor Biopharma is more favorable than Structure Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vor Biopharma
1 Sell rating(s)
4 Hold rating(s)

6 Buy rating(s)

2 Strong Buy rating(s)
2.69
Structure Therapeutics
2 Sell rating(s)

1 Hold rating(s)

13 Buy rating(s)

3 Strong Buy rating(s)
2.89

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.79	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Structure Therapeutics	N/A	-25.90%	-24.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Vor Biopharma beats Structure Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Vor Biopharma (NASDAQ:VOR) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

: Vor Biopharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vor Biopharma N/A N/A N/A -$386.83 N/A
Arcutis Biotherapeutics $376.07M 7.79 -$16.14M -$0.14 N/A
: Vor Biopharma currently has a consensus target price of $50.56, indicating a potential upside of 225.74%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 45.18%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vor Biopharma is more favorable than Arcutis Biotherapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vor Biopharma
1 Sell rating(s)
4 Hold rating(s)

6 Buy rating(s)

2 Strong Buy rating(s)
2.69
Arcutis Biotherapeutics
1 Sell rating(s)

2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.50
: 97.3% of Vor Biopharma shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: In the previous week, Vor Biopharma had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 6 mentions for Vor Biopharma and 5 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.00 beat Vor Biopharma's score of 0.92 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vor Biopharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcutis Biotherapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
: Vor Biopharma has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -4.29%. Vor Biopharma's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Vor Biopharma N/A N/A N/A
Arcutis Biotherapeutics -4.29% -10.26% -4.30%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Arcutis Biotherapeutics	$376.07M	7.79	-$16.14M	-$0.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Arcutis Biotherapeutics	-4.29%	-10.26%	-4.30%

Summary

Vor Biopharma beats Arcutis Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Vor Biopharma compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

: Denali Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics N/A N/A -$512.54M -$2.97 N/A
Vor Biopharma N/A N/A N/A -$386.83 N/A
: Denali Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 84.99%. Vor Biopharma has a consensus target price of $50.56, indicating a potential upside of 225.74%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Denali Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
1 Sell rating(s)
1 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.88
Vor Biopharma
1 Sell rating(s)

4 Hold rating(s)

6 Buy rating(s)

2 Strong Buy rating(s)
2.69
: In the previous week, Denali Therapeutics had 4 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Denali Therapeutics and 6 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.92 beat Denali Therapeutics' score of 0.91 indicating that Vor Biopharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vor Biopharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Denali Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.
: Vor Biopharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Denali Therapeutics N/A -50.13% -44.20%
Vor Biopharma N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.97	N/A
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vor Biopharma	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-50.13%	-44.20%
Vor Biopharma	N/A	N/A	N/A

Summary

Vor Biopharma beats Denali Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

: 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Vor Biopharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Gemini Therapeutics N/A -38.78% -35.88%
Vor Biopharma N/A N/A N/A
: Gemini Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A
Vor Biopharma N/A N/A N/A -$386.83 N/A
: In the previous week, Vor Biopharma had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 6 mentions for Vor Biopharma and 1 mentions for Gemini Therapeutics. Vor Biopharma's average media sentiment score of 0.92 beat Gemini Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gemini Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vor Biopharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.
: Vor Biopharma has a consensus target price of $50.56, indicating a potential upside of 225.74%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Gemini Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Vor Biopharma
1 Sell rating(s)

4 Hold rating(s)

6 Buy rating(s)

2 Strong Buy rating(s)
2.69

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Vor Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vor Biopharma	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

Summary

Vor Biopharma beats Gemini Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Dyne Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Dyne Therapeutics (NASDAQ:DYN) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

: 97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: In the previous week, Vor Biopharma and Vor Biopharma both had 6 articles in the media. Dyne Therapeutics' average media sentiment score of 0.95 beat Vor Biopharma's score of 0.92 indicating that Dyne Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vor Biopharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dyne Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Vor Biopharma currently has a consensus price target of $50.56, suggesting a potential upside of 225.74%. Dyne Therapeutics has a consensus price target of $35.14, suggesting a potential upside of 101.16%. Given Vor Biopharma's higher possible upside, equities research analysts plainly believe Vor Biopharma is more favorable than Dyne Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vor Biopharma
1 Sell rating(s)
4 Hold rating(s)

6 Buy rating(s)

2 Strong Buy rating(s)
2.69
Dyne Therapeutics
1 Sell rating(s)

2 Hold rating(s)

11 Buy rating(s)

3 Strong Buy rating(s)
2.94
: Vor Biopharma has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
: Dyne Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vor Biopharma N/A N/A N/A -$386.83 N/A
Dyne Therapeutics N/A N/A -$446.21M -$3.54 N/A
: Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Vor Biopharma N/A N/A N/A
Dyne Therapeutics N/A -61.46% -50.94%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$386.83	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Dyne Therapeutics	N/A	-61.46%	-50.94%

Summary

Vor Biopharma and Dyne Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$840.97M	$362.87M	$4.21B	$11.87B
Dividend Yield	N/A	N/A	5.61%	5.21%
P/E Ratio	-0.04	N/A	23.40	28.47
Price / Sales	N/A	372.54	186.69	60.92
Price / Cash	N/A	N/A	52.82	36.52
Price / Book	N/A	2.81	38.31	6.67
Net Income	N/A	-$81.71M	$114.66M	$332.53M
7 Day Performance	7.93%	6.50%	1.23%	2.01%
1 Month Performance	-14.02%	5.53%	5.54%	9.19%
1 Year Performance	N/A	N/A	18.68%	39.59%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	3.5661 of 5 stars	$15.52 +5.5%	$50.56 +225.7%	N/A	$840.97M	N/A	N/A	140
GPCR Structure Therapeutics	2.7652 of 5 stars	$42.21 +1.8%	$109.25 +158.8%	N/A	$2.99B	N/A	N/A	136	Upcoming Earnings
ARQT Arcutis Biotherapeutics	3.3955 of 5 stars	$23.35 +0.6%	$34.00 +45.6%	N/A	$2.92B	$376.07M	N/A	150	Upcoming Earnings
DNLI Denali Therapeutics	3.0503 of 5 stars	$18.30 -2.2%	$35.00 +91.3%	N/A	$2.90B	$330.53M	N/A	430	News Coverage Upcoming Earnings
GMTX Gemini Therapeutics	N/A	$66.91 +1.5%	N/A	N/A	$2.90B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. GPCR, ARQT, DNLI, GMTX, and DYN

How does Vor Biopharma compare to Structure Therapeutics?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Vor Biopharma compare to Denali Therapeutics?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. GPCR, ARQT, DNLI, GMTX, and DYN

How does Vor Biopharma compare to Structure Therapeutics?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Vor Biopharma compare to Denali Therapeutics?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools